Scientific Sessions 2024  /  GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics  /  Patient Interview
Logo

American Heart Association

  55
  0

Final ID:

Patient Interview

  • Ndumele, Chiadi  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Taub, Pam  ( UCSD MEDICAL CENTER , La Jolla , California , United States )
    • Author Disclosures:
    Chiadi Ndumele: DO NOT have relevant financial relationships | Pam Taub: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Consultant:Boehringer Ingelheim/Lilly:Active (exists now) ; Consultant:Sanofi:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Edwards:Active (exists now) ; Consultant:Esperion:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Main Event

More abstracts on this topic:
Panel Discussion

Tuttle Katherine

The cardiovascular benefits of incretin analogues: Suggestions of indirect and direct vascular effects

Mcmurray John, Sattar Naveed

More abstracts from these authors:
Panelist - Prevention

Taub Pam

The Hidden Risk Factor: The Underappreciated Aspects of Lp(a) in ASCVD

Kaul Sanjay, Taub Pam

You have to be authorized to contact abstract author. Please, Login
Not Available